BMJ Open

Association between the preoperative triglyceride-glucose index and myocardial injury following non-cardiac surgery: a cross-sectional study

Yuanjun Zhou [ID],[1] Weiming Chen,[2] Fei Liang,[2] Liping Zhong,[1] Yilin Liao,[1] Yuting Zhong[1]

[1]Department of Anaesthesiology, Meizhou People's Hospital, Meizhou, Guangdong, China
[2]Department of Medical Data, Meizhou People's Hospital, Meizhou, Guangdong, China

Correspondence to
Dr Yuting Zhong;
mzhospitalytzhong@163.com

ABSTRACT

Objective An elevated triglyceride-glucose (TyG) index positively correlates with adverse cardiovascular events. However, its association with myocardial injury after non-cardiac surgery (MINS) remains unclear. This study aimed to examine the association between the preoperative TyG index and MINS.

Design A cross-sectional study.

Setting Meizhou People's Hospital.

Participants Adult patients under general anaesthesia and with MINS.

Main exposure measure The preoperative TyG index, calculated using triglyceride (TG) and fasting blood glucose (FBG) levels.

Main outcome measure The occurrence of MINS, defined using postoperative troponin measurements.

Results 889 patients were included, with an 8.3% incidence of MINS (74/889). The median TyG index was 8.57 (8.13, 9.02). TyG exhibited higher discriminatory ability for MINS than TG and FBG, with an area under the curve of 0.624, 0.544 and 0.500, respectively. Fully adjusted logistic regression indicated that an elevated TyG index was independently associated with MINS (OR 1.75, 95% CI 1.21 to 2.52; p=0.003). A multivariate restricted cubic spline suggested a linear relationship between TyG and MINS (p value for non-linearity=0.059). Subgroup analyses showed results consistent with the primary analysis, with no significant interaction effects between subgroups.

Conclusion An elevated preoperative TyG index is independently associated with an increased incidence of MINS. Monitoring the TyG index perioperatively may improve the management of patients at risk for MINS.

Trial registration number ChiCTR2400082834.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Postoperative troponin levels were used to diagnose myocardial injury after non-cardiac surgery (MINS) to enhance the diagnostic objectivity and accuracy.

⇒ We demonstrated a non-linear and independent association between the triglyceride-glucose (TyG) index and MINS through rigorous adjustment for multiple confounding variables overlooked in previous research.

⇒ This study enhances the applicability of the TyG index-MINS relationship across broader age demographics, while addressing a critical gap in previous research.

⇒ A causal relationship cannot be established between preoperative TyG and MINS due to the study design.

INTRODUCTION

Myocardial injury after non-cardiac surgery (MINS) occurs in approximately 3%–16% of surgical cases[1–3] and is a significant cause of mortality within 30 days postoperatively.[1 4] The pathophysiology of MINS includes the disruption of atherosclerotic coronary plaques and an imbalance between myocardial oxygen supply and demand. Preoperative coronary angiography is not mandatory for individuals with coronary artery disease (CAD) who do not exhibit apparent myocardial ischaemic symptoms, making it challenging to identify high-risk patients preoperatively. Therefore, clinicians need a convenient and practical index for this purpose. Significant risk factors for CAD include dyslipidaemia and hyperglycaemia. Both obesity[5] and hyperglycaemia[6] have been strongly associated with subclinical myocardial injury (SCeMI) and adverse cardiovascular events (ACEs).

The triglyceride-glucose (TyG) index, derived from triglycerides (TGs) and fasting blood glucose (FBG), has been linked to the severity of CAD and ACEs.[7–10] Elevated TyG index levels are associated with increased severity of coronary artery stenosis and a higher number of diseased vessels in patients with acute coronary syndrome (ACS).[11 12] The TyG index is a robust predictor of subclinical CAD, even without traditional cardiovascular risk factors (CVRFs).[13] Furthermore, Kim *et al* demonstrated a correlation between higher TyG index levels and the presence of coronary artery calcification plaques in healthy

adults.[14] This observation suggests that patients indicated for operation who have a high TyG index and undergo general anaesthesia may possess underlying coronary artery atherosclerosis and a heightened risk of MINS, regardless of CVRFs. Since dyslipidaemia and hyperglycaemia are routinely detectable and modifiable preoperatively, understanding the relationship between MINS and the TyG index is crucial for perioperative management. However, there is limited research on this issue. Therefore, the clinical records from Meizhou People's Hospital were reviewed to investigate whether preoperative TyG levels were associated with MINS. Elevated preoperative TyG index was hypothesised as an independent risk factor for developing MINS.

METHODS AND MATERIALS
Data source
This study used medical records from Meizhou People's Hospital, including the electronic medical record system, surgical anaesthesia system, prescription system and laboratory and examination systems. The department of medical data and the department of medical administration granted access to these records. WC and FL were responsible for data extraction and cleaning, adhering to the study protocol.

Study population
Inclusion criteria: patients indicated for operation aged ≥40 years, who were administered general anaesthesia and those with troponin measurements recorded within 3 postoperative days. Exclusion criteria: (1) patients <40 years; (2) patients admitted without FBG and TG measurements; (3) patients lacking prescription information.

Exposure of interest
The primary exposure was the preoperative TyG index, calculated using the formula: TyG=ln (TG (mg/dL)×FBG (mg/dL)/2).[15 16] The conversion formulae used were FBG (mg/dL)=FBG (mmol/L)×18.0 and TG (mg/dL)=TG (mmol/L)×88.6. If FBG and TG were measured multiple times preoperatively, the closest measurements to the operation time were used.

Variables
The potential variables were categorised into four groups: (1) demographic characteristics, including age, gender and body mass index (BMI); (2) preoperative comorbidities, including congestive heart failure, hypertension, CAD, chronic obstructive pulmonary disease (COPD), diabetes, history of stroke and peripheral vascular disease (PVD); (3) preoperative laboratory results, including haemoglobin and estimated glomerular filtration rate (eGFR); (4) surgical information, including the American Society of Anesthesiologists Physical Status Classification System, highest intraoperative heart rate to mean arterial pressure, duration of anaesthesia and surgical categories.

Outcomes
The outcome of interest was MINS, defined by postoperative troponin levels exceeding the 99th percentile upper reference limit without non-ischaemic causes.[17 18]

Statistical analysis
This study included as many individuals as possible; therefore, no power calculation was conducted. The random forest algorithm was used for multiple imputations of variables with <20% missing data. Variables with >20% missing data were excluded to avoid bias. Patients were categorised into four groups based on the TyG index quartiles. Categorical variables were expressed as proportions. χ^2 test and Fisher's exact test were used for unordered categorical variables and Kruskal-Wallis tests for ordered categorical variables. Continuous variables, expressed as median (IQR) due to non-normal distribution (per Shapiro-Wilk test), were analysed using the Mann-Whitney U test or Kruskal-Wallis rank sum tests. The diagnostic performance of TyG for MINS was assessed using receiver operating characteristic (ROC) curves to determine the best cut-off value. Logistic regression analysis identified factors influencing MINS across three models. Model 1: unadjusted; Model 2: adjusted for variables with a p value <0.2 in the univariate analysis, along with clinically relevant variables; Model 3: adjusted for all predefined variables. OR and 95% CI were calculated for TyG and the outcome. The linear trend (p value trend) was assessed, and a multivariate restricted cubic spline (RCS) model analysed the non-linear relationship between baseline TyG and MINS. Post-hoc subgroup analyses were stratified by age (≤69 years and >69 years), gender, BMI (<25 kg/m^2 and ≥25 kg/m^2), hypertension and surgical category, with interaction effects tested between subgroups.

A p value <0.05 indicated statistical significance in two-tailed tests. Based on the open-source R, all statistical analyses were conducted using Stata software (https://www.mstata.com/).

Patient and public involvement
This study did not involve members of the public or patients.

RESULTS
Reporting guideline
This study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.[19]

Patient characteristics
A total of 889 patients undergoing general anaesthesia were included in the study (figure 1). Patients were categorised into four groups based on their TyG index (table 1). The TyG ranges for each group are specified in table 1. More than half of the patients were men, with a median age of 64 years. The overall median TyG index for all patients was 8.57, and the incidence of MINS was 8.3%. The fourth quartile (Q4) group generally exhibited

Figure 1 Flowchart of the study population. Flow diagram illustrating the inclusion and exclusion of cases. TG, triglyceride.

a higher BMI and a higher prevalence of preoperative hypertension, diabetes and history of stroke. Patients with a lower TyG index exhibited a lower incidence of MINS than those with a higher TyG index (p=0.009).

Baseline characteristics of patients with and without MINS

Online supplemental table S1 details the differences between the MINS and non-MINS groups. The median TyG index was significantly higher in the MINS group than in the non-MINS group (p<0.001). The two groups significantly differed in preoperative eGFR (p=0.002). Moreover, the MINS group exhibited a significantly higher occurrence of COPD, a history of stroke and PVD. Preoperative statin use was significantly lower in the non-MINS group (p=0.027).

ROC analysis

The TyG index demonstrated higher discriminatory accuracy for MINS than TG and FBG, with an area under the curve of 0.624, 0.544 and 0.500, respectively (online supplemental figure S1). The optimal cut-off value for the TyG index was identified as 8.73 (63.2% specificity and 60.8% sensitivity).

Multivariable logistic regression

The continuous TyG index was positively associated with MINS in the crude and adjusted models (table 2). Neither the Q2 nor the Q3 group exhibited a significantly different risk of MINS than the Q1 group. However, the Q4 group exhibited a substantially increased risk of MINS across all models. A significant linear (p value) trend was observed across Models 1, 2 and 3.

RCS analysis

The RCS analysis revealed a linear increase in the risk of MINS with rising TyG index values (p value for non-linearity=0.059) (figure 2). The reference point was set at 8.58, consistent with the optimal cut-off value of 8.73 derived from the ROC analysis.

Subgroup analysis

For clinical application, patients were categorised into two groups based on the TyG index (≤8.73 vs >8.73) to examine subgroup heterogeneity (figure 3). A TyG index >8.73 was particularly prominent in the following subgroups: patients ≤69 years, female patients, patients with a BMI <25 kg/m², patients without hypertension and patients undergoing non-thoracic surgery. There was no considerable interaction effect among these subgroups.

DISCUSSION

This study reveals that an elevated preoperative TyG index is independently associated with MINS. Our research provides a novel perspective for risk stratification and management strategies related to MINS. Previous research on the relationship between the preoperative TyG index and postoperative ACEs has been limited.

The TyG index demonstrates greater clinical utility than the homeostasis model assessment of insulin resistance (HOMA-IR) for evaluating insulin resistance (IR) and predicting metabolic disease risk.[20] Its key advantage lies in operational efficiency: HOMA-IR requires fasting insulin measurements, which are often unavailable in low-resource settings, thereby limiting its clinical accessibility. In contrast, the TyG index can be calculated using two routinely measured preoperative parameters—TG and FBG. Recent studies have confirmed a significant positive association between elevated TyG index and several cardiovascular disorders,[21] including heart failure,[22] ACS and CAD,[9 23] arterial stiffness,[24] stroke,[25 26] ACEs[27] and atrial fibrillation.[28] However, the relationship between the preoperative TyG index and MINS remains ambiguous. According to Liu et al, the TyG index is a significant biomarker of SCeMI.[29] Similarly, our study demonstrates a correlation between an elevated preoperative TyG index and a greater risk of MINS, complementing these findings. Compared with FBG and TG, the TyG index demonstrates more robust diagnostic efficacy for MINS, possibly because it more comprehensively reflects the body's metabolic status and arterial disease state. The linear association between the preoperative TyG index and MINS suggests that the TyG index could be used to predict the incidence of MINS in patients indicated for operation. Consistent with previous studies,[29 30] a high TyG index is associated with MINS, even among patients without diabetes and with normal BMI. However, subgroup analysis suggests that the predictive value of the TyG index is weakened in patients with obesity, diabetes and hypertension. These results may be attributed to differences in population characteristics and disease states, including cardiovascular system damage caused by hyperlipidaemia, diabetes and hypertension, and the interference of therapeutic drugs (statins, antidiabetics and antihypertensive drugs). Complex disease states may limit the predictive ability of the TyG index. In high-risk patients, individualised risk assessment requires a combination of multiple indicators to improve predictive accuracy.

Table 1 Baseline characteristics for patients stratified by TyG index quartiles

	Overall, n=889	Q1, n=223	Q2, n=222	Q3, n=222	Q4, n=222	P value
TyG index range	5.03–11.33	5.03–8.13	8.14–8.57	8.58–9.02	9.03–11.33	/
TyG index quartile	8.57 (8.13, 9.02)	7.85 (7.71, 8.03)	8.37 (8.25, 8.47)	8.75 (8.65, 8.89)	9.44 (9.21, 9.75)	<0.001
Age (years)	64 (55, 72)	64 (55, 73)	64 (55, 72)	65 (58, 73)	60 (54, 69)	<0.001
Sex (male)	533 (60.0)	137 (61.4)	148 (66.7)	115 (51.8)	133 (59.9)	0.015
BMI (kg/m^2)	22.1 (20.0, 24.6)	20.4 (18.7, 22.5)	21.9 (19.7, 24.0)	22.8 (20.8, 25.1)	23.5 (21.3, 25.5)	<0.001
Preoperative lab results						
Haemoglobin (g/L)	129 (112, 140)	124 (109, 137)	128 (112, 138)	130 (116, 140)	131 (114, 145)	0.010
eGFR (mL/min/1.73 m^2)	80 (68, 92)	81 (70, 93)	80 (70, 91)	78 (65, 91)	81 (68, 96)	0.220
Preoperative medical history						
CHF	19 (2.1)	4 (1.8)	4 (1.8)	7 (3.2)	4 (1.8)	0.753
Hypertension	199 (22.4)	27 (12.1)	40 (18.0)	60 (27.0)	72 (32.4)	<0.001
CAD	43 (4.8)	9 (4.0)	7 (3.2)	17 (7.7)	10 (4.5)	0.135
COPD	71 (8.0)	23 (10.3)	21 (9.5)	17 (7.7)	10 (4.5)	0.112
Diabetes	88 (9.9)	4 (1.8)	12 (5.4)	22 (9.9)	50 (22.5)	<0.001
Stroke	50 (5.6)	4 (1.8)	12 (5.4)	11 (5.0)	23 (10.4)	0.001
PVD	58 (6.5)	11 (4.9)	13 (5.9)	18 (8.1)	16 (7.2)	0.538
Preoperative medications						
Rate-controlling	38 (4.3)	9 (4.0)	8 (3.6)	14 (6.3)	7 (3.2)	0.362
Aspirin	26 (2.9)	6 (2.7)	6 (2.7)	7 (3.2)	7 (3.2)	0.983
Statins	81 (9.1)	16 (7.2)	18 (8.1)	25 (11.3)	22 (9.9)	0.442
ASA classification						0.888
I-II	57 (6.4)	12 (5.4)	17 (7.7)	13 (5.9)	15 (6.8)	
III	555 (62.4)	141 (63.2)	139 (62.6)	143 (64.4)	132 (59.5)	
IV-V	277 (31.2)	70 (31.4)	66 (29.7)	66 (29.7)	75 (33.8)	
Duration of anaesthesia (min)	200 (135, 260)	205 (140, 266)	200 (135, 274)	205 (140, 259)	184 (135, 245)	0.134
The highest intraoperative HMR	1.32 (1.13, 1.62)	1.30 (1.10, 1.54)	1.32 (1.11, 1.64)	1.33 (1.16, 1.65)	1.33 (1.15, 1.65)	0.248
Surgical procedures						0.002
Low-risk	47 (5.3)	12 (5.4)	13 (5.9)	3 (1.4)	19 (8.6)	
Thoracic	201 (22.6)	60 (26.9)	55 (24.8)	53 (23.9)	33 (14.9)	
Non-thoracic major	641 (72.1)	151 (67.7)	154 (69.4)	166 (74.8)	170 (76.6)	
Intraoperative bleeding (ml)	50 (20, 100)	50 (20, 100)	50 (20, 100)	50 (20, 100)	50 (15, 100)	0.405
Outcomes						
MINS within postoperative 3 days	74 (8.3)	10 (4.5)	15 (6.8)	20 (9.0)	29 (13.1)	0.009
Other variables						
TG (mmol/L)	1.19 (0.82, 1.68)	0.70 (0.59, 0.82)	1.04 (0.90, 1.22)	1.46 (1.20, 1.70)	2.16 (1.65, 3.07)	<0.001
Glucose (mmol/L)	5.38 (4.65, 6.83)	4.63 (4.15, 5.30)	5.13 (4.60, 6.04)	5.52 (4.96, 6.63)	7.22 (5.73, 10.25)	<0.001

ASA, American Society of Anesthesiologist; BMI, body mass index; CAD, coronary arterial disease; CHF, Congestive Heart Failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate (CKD-EPI formula); HMR, heart rate to mean arterial pressure; TyG index, triglyceride-glucose index; MINS, myocardial injury after non-cardiac surgery; PVD, peripheral vascular disease.

Emerging evidence aligns with our findings, demonstrating that the atherogenic index of plasma (AIP) independently predicts MINS.[31] These investigations synergistically highlight the clinical utility of preoperative metabolic profiling for stratifying postoperative ACEs.

While the AIP study focused specifically on the TG-to-high density lipoprotein ratio as a lipid-centric predictor, our TyG index analysis extends this paradigm by evaluating the combined contribution of TG and glucose metabolism to perioperative cardiovascular risk. This complementary

Table 2 Univariate and multivariate logistic regression for TyG index and MINS

	Model 1		Model 2		Model 3	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Continuous TyG index per unit	1.72 (1.27 to 2.35)	<0.001	1.54 (1.11 to 2.15)	0.010	1.75 (1.21 to 2.52)	0.003
TyG index quartile group (range)						
Q1 (5.03–8.13)	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
Q2 (8.14–8.57)	1.54 (0.68 to 3.51)	0.301	1.27 (0.55 to 2.98)	0.575	1.44 (0.61 to 3.42)	0.404
Q3 (8.58–9.02)	2.11 (0.96 to 4.61)	0.062	1.90 (0.85 to 4.27)	0.118	2.21 (0.95 to 5.17)	0.066
Q4 (9.03–11.33)	3.20 (1.52 to 6.74)	0.002	2.63 (1.20 to 5.78)	0.016	3.37 (1.46 to 7.81)	0.005
P$_{trend}$	<0.001		0.006		0.002	

Model 1: crude. Model 2: adjusted for age, gender, COPD, PVD, CAD, history of stroke, rate-controlling medications, statins and eGFR. Model 3: adjusted for age, gender, BMI, preoperative haemoglobin, eGFR, CHF, hypertension, CAD, COPD, diabetes, history of stroke, PVD, rate-controlling medications, aspirin, statins, ASA classification, duration of anaesthesia, the highest intraoperative HMR, surgical procedures and intraoperative bleeding.
ASA, American Society of Anesthesiologist; BMI, body mass index; CAD, coronary arterial disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HMR, heart rate to mean arterial pressure; TyG index, triglyceride-glucose index; MINS, myocardial injury after non-cardiac surgery; PVD, peripheral vascular disease.

approach strengthens the rationale for incorporating multidimensional metabolic assessments into preoperative evaluation of postoperative ACEs. Our findings not only validate the TyG index's predictive capacity but crucially extend its clinical application through population diversification. Our results align with prior evidence demonstrating the TyG index's association with MINS in geriatric populations (≥65 years).[32] Notably, our investigation extends beyond this demographic by encompassing younger surgical patients (≥40 years), thereby broadening the validated clinical applicability of the TyG index across age groups under-represented in existing MINS research. This expanded patient spectrum addresses a critical knowledge gap, as current studies predominantly focus on elderly populations despite the growing prevalence of CVRFs in younger adults.[1 17 33] Moreover, our study advances the field by establishing a linear dose-response relationship between TyG index values and MINS risk—a


Figure 2 RCS of TyG and MINS. The central thick blue line represents the adjusted OR, with shaded bands indicating the 95% CI. The horizontal dotted line represents an OR of 1.0. The solid blue dot indicates the reference point for the TyG index (8.58). The ORs were adjusted for age, gender, CAD, COPD, stroke, PVD, rate-controlling medications, statins and eGFR. CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MINS, myocardial injury after non-cardiac surgery; PVD, peripheral vascular disease; RCS, restricted cubic spline; TyG index, triglyceride-glucose index.

Subgroup	≤ 8.73	> 8.73		Adjusted OR (95% CI)	P value	P for interaction
Overall	29/543 (5.3)	45/346 (13.0)		2.44 (1.46, 4.12)	0.001	
Age (years)						0.796
> 69	11/186 (5.9)	13/95 (13.7)		1.98 (0.77, 5.15)	0.154	
≤ 69	18/357 (5.0)	32/251 (12.7)		2.58 (1.37, 5.00)	0.004	
Gender						0.141
Man	23/335 (6.9)	28/198 (14.1)		1.77 (0.92, 3.38)	0.084	
Woman	6/208 (2.9)	17/148 (11.5)		4.11 (1.62, 11.88)	0.005	
Body mass index (kg/m²)						0.615
< 25	27/462 (5.8)	35/241 (14.5)		2.46 (1.40, 4.36)	0.002	
≥ 25	2/81 (2.5)	10/105 (9.5)		4.60 (1.08, 32.71)	0.066	
Hypertension						0.876
NO	24/451 (5.3)	31/239 (13.0)		2.42 (1.33, 4.42)	0.004	
YES	5/92 (5.4)	14/107 (13.1)		2.98 (0.96, 10.97)	0.074	
Diabetes						0.124
NO	27/522 (5.2)	39/279 (14.0)		2.91 (1.70, 5.04)	<0.001	
YES	2/21 (9.5)	6/67 (9.0)		7.14 (0.48, 301.71)	0.210	
Surgical procedure						0.820
Low risk	2/27 (7.4)	4/20 (20.0)		2.21 (0.18, 32.71)	0.531	
Thoracic	8/141 (5.7)	6/60 (10.0)		1.74 (0.39, 6.87)	0.436	
Non thoracic major	19/375 (5.1)	35/266 (13.2)		2.66 (1.45, 5.01)	0.002	

0.2   1   4   16   64   256

Figure 3 Post-hoc subgroup analysis. Forest plots depicting the relationship between the TyG index (≤8.73 and >8.73) and MINS. The ORs were adjusted for age, gender, CAD, COPD, stroke, PVD, rate-controlling medications, statins and eGFR. *No of events/total no. (%). CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MINS, myocardial injury after non-cardiac surgery; PVD, peripheral vascular disease; TyG index, triglyceride-glucose index.

finding not previously quantified in earlier investigations. These methodological refinements strengthen the TyG index's utility for preoperative risk stratification in diverse surgical populations.

The association between the TyG index and MINS can be explained through atherosclerosis and metabolic abnormalities. The TyG index is a biomarker of metabolic disorders and atherosclerotic and cardiovascular diseases.[16 34 35] It reflects the degree of CAD and is independently associated with coronary atherosclerosis in healthy adult populations.[9 14] The TyG index is closely associated with IR.[36–39] IR leads to endothelial dysfunction, increased inflammatory responses, accelerated foam cell formation and smooth muscle cell proliferation, which promote atherosclerosis and vascular plaque formation.[40 41] Moreover, IR may reflect platelet reactivity and endothelial-dependent vasodilation.[42] An elevated preoperative TyG index is associated with hypertension, hyperglycaemia and hyperlipidaemia, all of which enhance the risk of vascular inflammation, coagulation and atherosclerosis. These mechanisms contribute to SCeMI.[29] Perioperative haemodynamic changes, inflammatory responses and oxidative stress may exacerbate pre-existing SCeMI, leading to MINS. Further investigations are needed to elucidate the exact mechanisms associating an elevated TyG index with MINS.

This study highlights the clinical utility of the preoperative TyG index as a simple, cost-effective tool for identifying patients at elevated risk of MINS. Preoperative troponin testing is not routine unless patients have a known history of CAD or exhibit symptoms of myocardial ischaemia. The TyG index, more accessible than preoperative troponin, could serve as an alternative screening tool. It is associated with CAD severity, subclinical CAD, SCeMI and MINS. Clinicians should consider incorporating TyG index screening into preoperative assessments for patients aged ≥40 years undergoing general anaesthesia, particularly those without overt cardiovascular symptoms. A high TyG index could be helpful for preoperative assessments, including preoperative myocardial status evaluation and guidance for intervention strategies (eg, glycaemic control and lipid management). For patients with a preoperative TyG index >8.73, heightened vigilance is warranted, including troponin testing, coronary angiography and medical therapy (such as statins and aspirin), especially for those without a clear CAD history. Our findings suggest that preoperative TyG index evaluation could refine perioperative risk stratification and guide targeted interventions to mitigate MINS-related complications. Randomised controlled trials (RCTs) are necessary to verify the optimal strategies based on the preoperative TyG index evaluation.

Limitations
This study has several limitations. First, residual confounding factors may have introduced bias, such as excluding patients <40 years old and those lacking preoperative FBG and TG measurements. Second, preoperative troponin screening was not performed for all patients indicated for surgery, potentially missing those with preoperative myocardial injury and introducing selection bias. This study limited its troponin measurements to patients with myocardial ischaemia symptoms. Since asymptomatic myocardial injury is prevalent among postoperative patients, our study may not fully capture the potential association between the

preoperative TyG index and asymptomatic myocardial injury. Current guidelines recommend troponin measurements (Class I recommendation) for patients who develop myocardial ischaemia symptoms following non-cardiac surgeries. For those at high risk but without postoperative ischaemic signs, a Class IIb recommendation is given.[43] The high rate of missing glycated haemoglobin (HbA1c) data led to its exclusion from the primary analysis. However, multivariate logistic regression analysis on the subset of data containing HbA1c yielded results consistent with the primary analysis (online supplemental table S2). Third, our study focused solely on the association between baseline TyG index and MINS. Future RCTs are essential to determine the impact of variations in the TyG index on MINS prevention, mainly through preoperative interventions targeting lipid and glucose levels.

CONCLUSION

An elevated preoperative TyG index is positively associated with a higher incidence of MINS. It can be used to assess the risk of MINS preoperatively. Further research is required to determine if controlling and monitoring the TyG index can reduce postoperative ACEs.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The Ethical Review Board of Meizhou People's Hospital reviewed the study protocol and approved this study, and informed consent was not required (Ethic No. 2023-C-92). We have also registered this study at the Chinese Clinical Trial Registry (No. ChiCTR2400082834).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The corresponding author can grant data access to this study upon request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iD
Yuanjun Zhou http://orcid.org/0000-0002-6709-8546

REFERENCES

1. Devereaux PJ, Chan MTV, Alonso-Coello P, *et al*. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. *JAMA* 2012;307:2295–304.
2. van Waes JAR, Grobben RB, Nathoe HM, *et al*. One-Year Mortality, Causes of Death, and Cardiac Interventions in Patients with Postoperative Myocardial Injury. *Anesth Analg* 2016;123:29–37.
3. Puelacher C, Lurati Buse G, Seeberger D, *et al*. Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. *Circulation* 2018;137:1221–32.
4. Devereaux PJ, Xavier D, Pogue J, *et al*. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. *Ann Intern Med* 2011;154:523–8.
5. Ndumele CE, Coresh J, Lazo M, *et al*. Obesity, subclinical myocardial injury, and incident heart failure. *JACC Heart Fail* 2014;2:600–7.
6. Rubin J, Matsushita K, Ballantyne CM, *et al*. Chronic hyperglycemia and subclinical myocardial injury. *J Am Coll Cardiol* 2012;59:484–9.
7. Tao LC, Xu JN, Wang TT, *et al*. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. *Cardiovasc Diabetol* 2022;21:68.
8. Cui H, Liu Q, Wu Y, *et al*. Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study. *Cardiovasc Diabetol* 2022;21:22.
9. Liang S, Wang C, Zhang J, *et al*. Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis. *Cardiovasc Diabetol* 2023;22:170.
10. Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, *et al*. The TyG index may predict the development of cardiovascular events. *Eur J Clin Invest* 2016;46:189–97.
11. Mao Q, Zhou D, Li Y, *et al*. The Triglyceride-Glucose Index Predicts Coronary Artery Disease Severity and Cardiovascular Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. *Dis Markers* 2019;2019:6891537.
12. Shali S, Luo L, Yao K, *et al*. Triglyceride-glucose index is associated with severe obstructive coronary artery disease and atherosclerotic target lesion failure among young adults. *Cardiovasc Diabetol* 2023;22:283.
13. Park G-M, Cho Y-R, Won K-B, *et al*. Triglyceride glucose index is a useful marker for predicting subclinical coronary artery disease in the absence of traditional risk factors. *Lipids Health Dis* 2020;19:7.
14. Kim MK, Ahn CW, Kang S, *et al*. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. *Cardiovasc Diabetol* 2017;16:108.
15. Liu D, Yang K, Gu H, *et al*. Predictive effect of triglyceride-glucose index on clinical events in patients with acute ischemic stroke and type 2 diabetes mellitus. *Cardiovasc Diabetol* 2022;21:280.
16. Zhang R, Shi S, Chen W, *et al*. Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database. *Cardiovasc Diabetol* 2023;22:10.
17. Ruetzler K, Smilowitz NR, Berger JS, *et al*. Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association. *Circulation* 2021;144:e287–305.
18. Thygesen K, Alpert JS, Jaffe AS, *et al*. Fourth Universal Definition of Myocardial Infarction (2018). *Circulation* 2018;138:e618–51.
19. Ghaferi AA, Schwartz TA, Pawlik TM. STROBE Reporting Guidelines for Observational Studies. *JAMA Surg* 2021;156:577–8.
20. Son D-H, Lee HS, Lee Y-J, *et al*. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. *Nutr Metab Cardiovasc Dis* 2022;32:596–604.
21. Liu X, Tan Z, Huang Y, *et al*. Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. *Cardiovasc Diabetol* 2022;21:124.
22. Khalaji A, Behnoush AH, Khanmohammadi S, *et al*. Triglyceride-glucose index and heart failure: a systematic review and meta-analysis. *Cardiovasc Diabetol* 2023;22:244.
23. Jin J-L, Cao Y-X, Wu L-G, *et al*. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. *J Thorac Dis* 2018;10:6137–46.
24. Liu F, Ling Q, Xie S, *et al*. Association between triglyceride glucose index and arterial stiffness and coronary artery calcification: a systematic review and exposure-effect meta-analysis. *Cardiovasc Diabetol* 2023;22:111.

25 Yang Y, Huang X, Wang Y, *et al*. The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis. *Cardiovasc Diabetol* 2023;22:2.

26 Kourtidou C, Ztriva E, Kostourou D-T, *et al*. The Predictive Role of the Triglyceride/Glucose Index in Patients with Hypercholesterolemia and Acute Ischemic Stroke. *Rev Cardiovasc Med* 2022;23:399.

27 Zhang J, Hou Q, Han Q, *et al*. Prediction of Major Adverse Cardiovascular Events by Triglyceride Glucose Index in Predominantly Male Patients with Rheumatoid Arthritis. *Rev Cardiovasc Med* 2024;25:28.

28 Azarboo A, Behnoush AH, Vaziri Z, *et al*. Assessing the association between triglyceride-glucose index and atrial fibrillation: a systematic review and meta-analysis. *Eur J Med Res* 2024;29:118.

29 Liu Y, Wu M, Xu J, *et al*. Association between Triglyceride and glycose (TyG) index and subclinical myocardial injury. *Nutr Metab Cardiovasc Dis* 2020;30:2072–6.

30 Simental-Mendía LE, Hernández-Ronquillo G, Gómez-Díaz R, *et al*. The triglycerides and glucose index is associated with cardiovascular risk factors in normal-weight children and adolescents. *Pediatr Res* 2017;82:920–5.

31 Zhou Y, Zhong L, Liao Y, *et al*. The relationship between the atherogenic index of plasma and postoperative myocardial injury following non-cardiac surgery under general anaesthesia: a retrospective cohort study. *BMC Cardiovasc Disord* 2025;25:75.

32 Yao S, Zhang K, Yang Y, *et al*. Relationship between preoperative high triglyceride-glucose index and myocardial injury following non-cardiac surgery in advanced-age patients: a retrospective cohort study. *Diabetol Metab Syndr* 2024;16:120.

33 Writing Committee for the VISION Study Investigators, Devereaux PJ, Biccard BM, *et al*. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. *JAMA* 2017;317:1642–51.

34 Zhou Y, Pan Y, Yan H, *et al*. Triglyceride Glucose Index and Prognosis of Patients With Ischemic Stroke. *Front Neurol* 2020;11:456.

35 Zhao Q, Cheng Y-J, Xu Y-K, *et al*. Comparison of various insulin resistance surrogates on prognostic prediction and stratification following percutaneous coronary intervention in patients with and without type 2 diabetes mellitus. *Cardiovasc Diabetol* 2021;20:190.

36 Zhao Q, Zhang T-Y, Cheng Y-J, *et al*. Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. *Cardiovasc Diabetol* 2020;19:108.

37 Ahn N, Baumeister SE, Amann U, *et al*. Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes. *Sci Rep* 2019;9:9693.

38 Mohd Nor NS, Lee S, Bacha F, *et al*. Triglyceride glucose index as a surrogate measure of insulin sensitivity in obese adolescents with normoglycemia, prediabetes, and type 2 diabetes mellitus: comparison with the hyperinsulinemic-euglycemic clamp. *Pediatr Diabetes* 2016;17:458–65.

39 Chamroonkiadtikun P, Ananchaisarp T, Wanichanon W. The triglyceride-glucose index, a predictor of type 2 diabetes development: A retrospective cohort study. *Prim Care Diabetes* 2020;14:161–7.

40 Yang Q, Vijayakumar A, Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism. *Nat Rev Mol Cell Biol* 2018;19:654–72.

41 Gao S, Ma W, Huang S, *et al*. Impact of triglyceride-glucose index on long-term cardiovascular outcomes in patients with myocardial infarction with nonobstructive coronary arteries. *Nutr Metab Cardiovasc Dis* 2021;31:3184–92.

42 Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. *J Clin Invest* 2016;126:12–22.

43 Fleisher LA, Fleischmann KE, Auerbach AD, *et al*. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;130:2215–45.